Jefferies analyst Dennis Ding assumed coverage of Olema Oncology (OLMA) with a Buy rating and price target of $40, down from $43. The firm views Olema as a “high quality” oncology company with multiple Phase III breast cancer studies for its “potent” oral CERAN plus KAT6 pipeline. The Phase I KAT6 data in Q2 could expand the oncology franchise beyond breast cancer, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology price target raised to $58 from $55 at JPMorgan
- Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
- Olema Oncology price target lowered to $38 from $40 at Guggenheim
- Olema Oncology price target raised to $62 from $60 at Citi
- Olema Pharmaceuticals: Palazestrant Phase III Upside and Differentiated Pipeline Underpin Buy Rating